Actively Recruiting
A Study of APL-10456-Vaccine
Led by Apollo Therapeutics Ltd · Updated on 2026-05-04
144
Participants Needed
2
Research Sites
87 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
AP09CP01 is a Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study which is conducted in Australia. The main purpose of this research study is to evaluate the safety, side effects, and immune response of APL-10456-Vaccine, a Rhinovirus (RV) Vaccine, when compared with a placebo in Younger and Older Healthy Volunteers
CONDITIONS
Official Title
A Study of APL-10456-Vaccine
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 54 years for Part A and 55 years or older for Part B
- Healthy participants as determined by medical history, physical examination, and investigator judgment
You will not qualify if you...
- History of severe allergic or anaphylactic reactions
- Acute illness or fever (temperature 38.0�b0C/100.4�b0F) within 72 hours before Day 1 visit
- Significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, psychiatric, or neurological disease within past 3 months
- Minor acute illness (e.g., cold, influenza, infection) within past 1 month if clinically relevant
- History of congenital or acquired immunodeficiency
- Skin conditions affecting local reaction assessments
- Bleeding disorders contraindicating injections or blood draws
- Cancer diagnosis within previous 5 years
- Systemic immunosuppressant use >14 days within 180 days before randomization
- Receipt or planned receipt of any licensed vaccine (including COVID-19) within 28 days before or after study injection
- Use or planned use of systemic immunoglobulins, long-acting biological therapies, or blood products within 90 days before randomization
- Positive pregnancy test or lactating females
- Positive HIV, HCV, or HBsAg serology at screening
- Positive drug abuse test at screening
- Participation in other interventional clinical studies within 3 months before randomization or planned during this study
- Blood donation of 450 mL within 28 days before randomization or planned during study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Emeritus Research
Melbourne, Victoria, Australia, 3124
Actively Recruiting
2
Veritus Research
Melbourne, Victoria, Australia, 3153
Actively Recruiting
Research Team
S
Sanjay Aggarwal, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here